Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.

Biotech Giants: Cost of Revenue Trends from 2014 to 2023

__timestamp	Celldex Therapeutics, Inc.	Lantheus Holdings, Inc.
Wednesday, January 1, 2014	101881000	176081000
Thursday, January 1, 2015	4011000	157939000
Friday, January 1, 2016	102026000	164073000
Sunday, January 1, 2017	96171000	169243000
Monday, January 1, 2018	66449000	168489000
Tuesday, January 1, 2019	42672000	172526000
Wednesday, January 1, 2020	42534000	200649000
Friday, January 1, 2021	3068000	237513000
Saturday, January 1, 2022	1400000	353358000
Sunday, January 1, 2023	3008000	586886000

Unleashing the power of data

Cost of Revenue: A Tale of Two Biotech Companies

In the competitive world of biotechnology, understanding cost structures is crucial. Lantheus Holdings, Inc. and Celldex Therapeutics, Inc. offer a fascinating study in contrasts. Over the past decade, Lantheus has consistently maintained a higher cost of revenue, peaking at nearly 587% more than Celldex in 2023. This trend reflects Lantheus's expansive operations and market reach. In contrast, Celldex's cost of revenue has seen significant fluctuations, with a dramatic drop of over 97% from 2014 to 2022, indicating strategic shifts or operational efficiencies. The data from 2014 to 2023 highlights the dynamic nature of the biotech industry, where cost management can be as critical as innovation. As these companies navigate the complexities of the market, their financial strategies offer valuable insights into the broader economic landscape.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025